Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant

Core Viewpoint - Daré Bioscience and Theramex have entered into a co-development and licensing agreement for a biodegradable contraceptive implant called Casea S, which is currently undergoing a fully funded Phase 1 study [2][3][5]. Company Overview - Daré Bioscience is focused on advancing innovative products for women's health, with a mission to develop a diverse portfolio of therapies that improve outcomes in areas such as contraception, sexual health, and menopause [6]. - Theramex is a global specialty pharmaceutical company dedicated to women's health, offering a range of products covering contraception, fertility, menopause, and osteoporosis [10]. Product Development - Casea S is designed to be a long-acting, minimally-invasive contraceptive that releases a contraceptive agent for 18-24 months before dissolving, eliminating the need for surgical removal [3][4]. - The ongoing Phase 1 study is fully funded by a foundation grant, meaning there are currently no development costs for either Daré or Theramex [5]. - If the Phase 1 study yields positive results, Daré will be responsible for conducting the subsequent Phase II study in the US, with funding for future studies to be shared between the two companies [5]. Leadership and Recognition - Daré's leadership has received accolades for their contributions to innovation in women's health, including recognition on Medicine Maker's Power List and Fierce Pharma's Most Influential People in Biopharma [8].